Trevi Therapeutics (TRVI) Treasury Shares (2018 - 2019)
Trevi Therapeutics' (TRVI) quarterly Treasury Shares came in at $22.6 million in Q1 2019, up 46.92% quarter-over-quarter from $15.4 million in Q4 2018.
Trevi Therapeutics (TRVI) Treasury Shares (2018 - 2019) Analysis & Trends
Trevi Therapeutics' Treasury Shares history runs 2 years deep, the most recent figure standing at $22.6 million for Q1 2019.
- On a quarterly basis, Treasury Shares changed N/A year-over-year to $22.6 million in Q1 2019; TTM through Mar 2019 was $22.6 million, a N/A change from a year earlier, with the FY2018 full-year figure at $76.1 million, changed N/A from the prior year.
- Treasury Shares climbed to $22.6 million in Q1 2019 per TRVI's latest filing, from $15.4 million in the prior quarter.
- Across five years, Treasury Shares topped out at $22.6 million in Q1 2019 and bottomed at $15.4 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -21,709.08 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 265,401.92 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 34.70 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 5.14 Mn |
| 10 | Trevi Therapeutics | 2.54 Bn | 2.54 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 22.61 Mn |
| Mar 31, 2019 | 22.61 Mn |
| Dec 31, 2018 | 15.39 Mn |
| Dec 31, 2018 | 15.39 Mn |